Week 3 - Lecture 3b - Clinical Models Pt. 2 Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

difference between Luekaemia and lymphoma

A

leukaemia is a term used for neoplasms with widespread involvement of the bone marrow and peripheral blood

lymphoma is used for proliferations that arise as discrete tissue Masses

check slides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

leukaemia pathophysiology

A

malignant neoplasms of blood and blood forming organs
most common cancer in children
- can occur in adults

classification is based on predominant cell type and condition

ALL
AML
CLL
CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are B cells

A

B-lymphocyte
mature into plasma cells that produce antibodies to fight off an infection
also other B cells mature into memory B-cells

T and B cells are part of the acquired immune system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are T cells

A

t-lymphocyte
type of white blood cell that circulates that body, scanning for cellular abnormalities and infections

killer T-cells and Helper T-cells
kill T cells have “x-ray vision” scan cells
helper T cells orchestrate an immune response to deal with germs and infection

T cells are responsible for rejection of a transplanted organ

  • virtually all autoimmune diseases ( diabetes, MS, RA)
  • allergic reactions for gluten intolerance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are natural killer cells

A

they are a type of lymphocyte and a component of the innate immune system
-play a main role in the host- rejection of both tumours and virally infected cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Acute leukaemia clinical manifestations

A

leukaemic cells are immature and poorly differentiated

  • proliferate and long life span
  • circulate in bloodstream, cross blood-brain barrier, infiltrate many body organs

80% of ALL has a B cell as precursor
-all is associated with
- alterations in the number of chromosomes
chromosomal translocation
-identifying alterations has prognostic significance

among non lymphocytic leukaemia :
myoblastic cell line involvement is prevalent - AML
- immature myeloid cells proliferate in bone marrow
-lack of ability to differentiate into specific functional blood cells
- anaemia (replaced by RBCs) leukopenia (reduced leukocytes) thrombocytopenia (reduced platelets)
chromosomal alterations have prognostic significance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Acute leukaemia clinical manifestations cont’

A

similar in ALL & in AML
sudden onset (acute) is related to
-immaturity of WBC’s and other cells originating in the bone marrow
- increased infection

  • crowding of leukaemic cells in bone marrow
    • suppressing RBC’s and platelet production
    • anaemia, bruising, bleeding problems: frequent nose bleeds (epistaxis)
    • anaemia leads to fatigue
    • crowding leads to increase pressure and pain
  • infiltration of leukaemic cells in the CNS, lymph nodes, liver, spleen
  • in lymph nodes, spleen, liver: enlargement and tenderness of organs

unexplained weight loss, fever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

acute leukaemia diagnostic criteria

A

history P/E

complete blood cell count
- >20% immature WBCs
cytologic examination of blood cells for leukaemia subtype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Acute Leukaemia treatment

ALL

A

ALL
systemic combination chemotherapy
prophylactic CNS intrathecal (into spinal canal) chemotherapy with and without radiation cranial radiation
- treatment protocol consists of induction, intensification, maintenance
-monitoring : myelosuppression and immunosuppression due to intense chemotherapy

goal : achieve remission

  • 95% of children with ALL achieve remission
  • 85% 5 survival rate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

AML Treatment

A

systemic combination chemotherapy in 2 phases:
1. introduction to achieve remission
2. post remission
70% adults with AML can expect complete remission

Better prognosis - younger age, lack of CNS involvement, lack of systemic infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

chronic leukaemia pathophysiology

A

gradual onset
most common in middle and older adults

CLL

  • over proliferation of B-lymphocytes
    • relatively mature but not fully functional
    • do not readily form antibodies in presence of antigens
  • infection

CML
insidious onset
immature myeloid cells are involved
relatively mature but not fully functional

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Chronic leukaemia patho 2

A

chronic leukaemia are differentiated by presenting

  • certain B-cell antigens
  • genetic aberrations
  • chromosomal aberrations

philadelphia chromosome in CML : 95%

  • chromosome 9 and 22 translocation
  • activates the ABL oncogene.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Chronic leukaemia clinical manifestations

A

subtle or not present until the disease is well advanced

once present, clinical manifestations are similar to acute leukaemia’s
*same as the acute *

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Chronic leukaemia diagnostic criteria

A

due to subtle onset, accidental diagnosis before symptom manifestations
complete blood count : elevated WBC count
Diagnosed through a bone marrow biopsy

cytologic examination of blood cells
- cytogenetic analysis of Philadelphia chromosome translocation (for CML diagnosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Chronic leukemia treatmetn

A

optimal treatment regimen is still under investigation
>50% patients may be cured by bone marrow or stem cell transplantation
- transplantation option Is limited
- age
- overall health
- inability to locate suitable donor
-extremely high WBCs (>100,000/mm3) ( normal value 5-10,000/mm3
- immediate chemotherapeutic treatment to avoid death from obstructed blood perfusion
- splenectomy may be required due to physical discomfort and haematologic disorders caused by enlargement

mediant survival

  • CLL 8-12 years
  • CML 4-6 yrs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Lymphoma pathophysiology

A

lymphomas (like some leukemias) have lymphoid stem cell origin
orm solid organ tumours in the lymph tissue and later in the bone marrow
diverse group of solid tumours

lymphoma can be present in the spleen

classified as
Hodgkin
non - hodgkin

17
Q

Hodgkin lymphoma pathophysiology

A

painless, progressive enlargement of cervical (neck) lymph nodes
exact cause unknown
risk factors
- exposure to viruses such as Epstein-Barr virus
-genetic factors
-Immunosuppression

Childhood form of HL is similar to the adult onset

  • 82% of children do not relapse within 5 years
  • 5 year survival rate is 95%

adult mortality has declined most among malignancies

  • improved radiation
  • improved chemotherapy
18
Q

Hodgkin lymphoma patho cont’

A

HL characterised by the presence of

  • binucleated/multinucleated giant cells (macrophages) : Reed-Sternberg cells
  • Mononuclear giant cells : Hodgkin cells
  • other inflammatory cells

pathogenesis is still unclear

  • Reed - Sternberg or Hodgkin cell is neoplastic origin with clonal section capability
  • RS cell originates in the cell components of lymph nodes following B lymphocyte linage

HL arises In B-cells that cannot synthesise immunoglobulin and are resistant to apoptosis
After the primary tumour established
- spread to contagious lymph nodes and can infiltrate vascular system
-HL is organ tropic to lung, liver, bones and bone marrow

19
Q

Hodgkin lymphoma patho pt 3

A

HL is classified according to histologic characteristics of affected cells

  • two main categories differ based on B-cell immunophemotypew
  • classic HL with subcategories
    -nodular lymphocyte dominant HL
    Staging ranges from
  • I (involvement of single lymph node) to
    IV (disseminated involvement of one or more organs outside the lymphatic system)

These stages are further divided
- A: absence of specific system manifestations
B: presence of specific system manifestations

Specific systemic manifestations are related to rapid growth of abnormal lymphoid cells and tissues
- unexplained weight loss / unexplained fever/ drenching night sweats

20
Q

Hodgkin lymphoma clinical manifestations

A

80% of patients with HL : nontender enlargement of cervical (neck) lymph nodes

  • lymph nodes are form and rubbery in texture
  • Reed-Sternberg or Hodgkin cells release inflammatory mediators lymphokines and cytokines
    • low grade fever, night sweats, pruritus, weight loss fatigue

20% of patients have mass at the mediastinum
- greater than 1/3 of chest diameter
Splenomegaly, hepatomegaly may also be present

21
Q

Lymphoma diagnostic criteria : Hodgkin

A
diagnosis and staging is based on 
history taking and P/E 
laboratory studies
thoracic and abdominal CT scans 
most signifant: presence of reed Sternberg cells
22
Q

Lymphoma treatment : hodgkin

A

treatment is based on clinical staging

  • 77% relapse free survival in all patients newly diagnosed with HL
  • Patient with stage IA or IIA are clinical early- stage
    • chemo
    • chemo radiation therapy
    • radiation therapy alone

Patients with stage III and IV
- combination therapy with / without adjunct radiation therapy

reduced doses are used for children

high risk patients (poor prognosis) : 42-51% 5 year survival rate

23
Q

Non hodgkin lymphoma

A

generic classifications of B-cell and T-cell malignancies with immune system
- NHL occurs more frequently than HL
-Does not exhibit Reed-Sternberg or Hodgkin cells
more likely to affect noncontagious lymph nodes
-aetiology Is unknown
- virus
- immunodeficiency
- genetic factors

24
Q

Pathophysiology of non-hodgkin lymphoma

A

genetic susceptibility is highly variable
depends on specific cell affected by neoplasia

follicular lymphoma : alterations of BCL-2 gene is present in 90% of patients

  • overexpression of BCL - 2 protein
  • BCL 2 prevents apoptosis, leading to overproliferation of lymph tissue

NHL can spread via lymphatic and vascular system

NHL organ tropic to liver, spleen, bone marrow

25
Q

non-hodgkin clinical manifestations

A

depends on tumour type and extent of disease
most common occurrence (as with HL)
Painless enlargement of lymph nodes
- other lymph nodes can also be affected

Specific systemic manifestations are related to rapid growth of abnormal lymphoid cells and tissues
- unexplained weight loss/unexplained fever/ drenching night sweats

increased risk of infection

paraneoplastic syndromes

26
Q

Diagnosis of NHL

A

history PE
lymph node biopsy to confirm NHL
histopathologic analysis. immunophenotyping to determine linage
chest and abdominal CT/MRI/PET scan to visualise tumour size and

27
Q

Treatment of NHL

A

treatment is based on categorising NHL’s into two prognostic groups
1. indolent (passive, painless) lymphomas